Episode 47. ASCO/EHA 2024 Lymphoma Updates with Dr. Gloria Iacoboni

https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/ec/ff/29/ecff295f-8f4c-e8f2-8d5c-0c8a88cb945e/mza_11191508321578000071.jpg/600x600bb.jpg

Blood Cancer Talks

Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff

67 episodes

1 month ago

This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth. Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk

All content for Blood Cancer Talks is the property of Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Education

Health & Fitness,

Medicine

Episode 47. ASCO/EHA 2024 Lymphoma Updates with Dr. Gloria Iacoboni

Blood Cancer Talks

47 minutes

1 year ago

Episode 47. ASCO/EHA 2024 Lymphoma Updates with Dr. Gloria Iacoboni

In this episode, we reviewed the hottest updates in lymphoma from ASCO and EHA 2024, held in Chicago and Madrid respectively, with Dr. Gloria Iacoboni, a haematologist from University Hospital Vall d'Hebron, in Barcelona, Spain. Here are the key abstracts we discussed:

1. STARGLO: Glofit-GEMOX vs R-GEMOX in relapsed/refractory DLBCL

https://library.ehaweb.org/eha/2024/eha2024-congress/4136516

2. Epco-Pola-R-CHP for 1st line DLBCL (EPCORE NHL-5 study):

https://library.ehaweb.org/eha/2024/eha2024-congress/422343

3. 3-year follow-up of TRANSFORM (Liso-Cel vs CITàASCT in R/R DLBCL): https://meetings.asco.org/abstracts-presentations/232740

4. ECHO RCT: Acalabrutinib-BR vs Placebo-BR in previously untreated elderly MCL: https://library.ehaweb.org/eha/2024/eha2024-congress/4136515

5. HD21: escBEACOPP vs BrECADD in 1st line classical HL: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01315-1/fulltext

6. Combination pirtobrutinib, venetoclax, and obinutuzumab in 1st line CLL: https://library.ehaweb.org/eha/2024/eha2024-congress/422268

7. Single-agent epcoritamab in Richter’s transformation: EPCORE CLL-1: https://library.ehaweb.org/eha/2024/eha2024-congress/422267